The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gavin Clark-Gartner - Evercore ISI - Analyst
: Congrats on the great progress. First, for the additional volixibat PBC data that's in the EASL abstract, it looks like the pruritus benefit deepened a
bit at 28 weeks. And also, I think there were no discontinuations due to diarrhea beyond the one you saw at 16 weeks. Maybe you can just speak
to that and anything else from the abstract there.
Question: Gavin Clark-Gartner - Evercore ISI - Analyst
: Great. And then just on the LIVMARLI tablet formulation. Can you just frame the additional IP that could come around with that? And also commercially,
where you see adoption of the tablet formulation?
Question: Jessica Fye - JPMorgan - Analyst
: Curious how you think your interim Phase II PBC data compares to the pruritus data for linerixibat? And also curious what you make of the placebo
response observed on pruritus in that trial. Then I have a second question.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 07, 2025 / 8:30PM, MIRM.OQ - Q1 2025 Mirum Pharmaceuticals Inc Earnings Call
Question: Jessica Fye - JPMorgan - Analyst
: Great. And then can you -- maybe switching to Fragile X. Can you just remind us what needs to happen between now and when you start Phase II
study in the back half?
Question: David Lebowitz - Citi - Analyst
: A couple of questions on the numbers regarding the inventory, which you said, I believe, was the first time this quarter. Should people see this as
being steady state right now? Or are you still learning about where, ultimately, inventory levels will sit. And on the one timers and whatnot in the
operating spend, could you just comment on what we should see in that regard later in the year?
Question: Ryan Deschner - Raymond James - Analyst
: Curious what your expectations for the impact of the tablet formulation of LIVMARLI on demand and competitive positioning is, as well as what
proportion of Alagille patients you think or you'd expect to opt for the tablet at a more steady state? And would you expect this to drive meaningful
switch demand.
| 
